Webinar 97: Update on cell technology, cell therapy, tissue engineering and gene therapy in Japan

Will Japan take the lead in regenerative medicine, a multi-billion € business? 

Following the development of iPS cell technology by Professor Shinya Yamanaka, Japan has taken decisive steps to turn this and related research results into business opportunities. Supported by eased regulations and major government programs, Japan now offers a very active research landscape, which includes RIKEN. Many startups have formed, major pharmaceutical firms have initiated R&D in this field, and other companies, notably from the camera industry, have joined in view of diversification. As a consequence of these often concerted efforts, many cellular drugs are now under advanced clinical studies, and the first products have entered the Japanese market. The webinar will update an earlier report of this series from 2015, showing that events in Japan have further accelerated. In addition, some reflections on how and why to join these dynamic developments as a EU company or startup will be provided. 

The webinar is targeted to EU companies seeking to partner or get into business with Japanese companies or startups active in regenerative medicine or gene therapy.

Registration deadline: 19/06/2017

What you will learn during this webinar?

In 40 minutes from your desk, discover how to:

• understand why Japan devotes so much energy on developing a market for cell products
• follow up on the major players in regenerative medicine and gene therapy in Japanese academia and industry
• understand how government regulations and coordinated R&D programs support this agenda
• consider strategies to partner or get into business with Japanese stakeholders

Programme:

• Introduction
• Expert’s presentation
• Q&A Session
• Conclusion

Speaker: Rolf Schmid, Director of Bio4Business 
Organiser: EU-Japan Centre for Industrial Cooperation - Brussels Office

After Event Information